Calcineurin Inhibitors

DRUG4 trials

Sponsors

Hoffmann-La Roche, Regimmune Corporation, Nanfang Hospital, Southern Medical University, RenJi Hospital

Conditions

Acute Graft-versus-host DiseaseDermatomyositisGraft Versus Host DiseaseKidney TransplantationLung; Disease, Interstitial, With Fibrosis

Phase 1

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

CompletedNCT01379209

Regimmune CorporationGraft Versus Host Disease

Start: 2011-09-30End: 2017-04-30Updated: 2019-10-23

Phase 2

MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD

Nanfang Hospital, Southern Medical UniversityAcute Graft-versus-host Disease

Start: 2014-09-30End: 2018-12-31Target: 200Updated: 2014-09-16

Basiliximab Treating Interstitial Pneumonia of CADM

RenJi HospitalDermatomyositis, Lung; Disease, Interstitial, With Fibrosis

Start: 2017-07-31End: 2020-06-30Target: 100Updated: 2017-06-20

Phase 4

Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients

CompletedNCT00121810

Hoffmann-La RocheKidney Transplantation

Start: 2003-08-31End: 2009-11-30Updated: 2011-04-15

Related Papers

Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trial.

2025-07-09

Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial

Journal of Hematology & Oncology2022-03-0784 citations